By a News Reporter-Staff News Editor at Pharma Business Week — According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Uniqure N.V. (Form 6-K) was posted on July 2, 2014.
The SIC code for this company is 2834, Pharmaceutical Preparations.
There were 3 documents filed with this form. The SEC file number is 0001104659-14-049827.
The contact information for this company is MEIBERGDREFF 61, AMSTERDAM P7 1005 BA, 31-20-5667394.
Our editors provided additional information about Form 6-K: This report is used by certain foreign private issuers to furnish information: (i) required to be made public in the country of its domicile; (ii) filed with and made public by a foreign stock exchange on which its securities are traded; or (iii) distributed to security holders. The report must be furnished promptly after such material is made public. The form is not considered “filed” for Section 18 liability purposes. This is the only information furnished by foreign private issuers between annual reports, since such issuers are not required to file on Forms 10-Q or 8-K.
A U.S. Securities and Exchange Commission filing is a formal document or financial statement submitted to the SEC by publicly-traded companies.
For additional information on this SEC filing see: http://www.sec.gov/Archives/edgar/data/1590560/0001104659-14-049827-index.html.
Keywords for this news article include: Pharmaceutical Preparations, SEC Filing, Uniqure N.V.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Uniqure N.V. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16] (Jul. 2, 2014)
By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission
- 2 min Read
- 07.9.2014
A weekly five-point roundup of critical events in the energy transition and the implications of climate change for business and finance.
I’m pro-renewable energy. But I’m against worshiping any technology and blindly glossing over its drawbacks.
The company is facing tons of issues. But are these temporary or more permanent?
Thanks to the leap AI’s made this past year, you can now clone any voice from a 30-second clip.
Alnylam’s promising research interests include genetic medicines, cardio-metabolic diseases, hepatic infectious diseases and more.
Gold investors, once optimistic, now exhibit caution and are often ’frozen.’
